| Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non–small cell lung cancer G Kichenadasse, JO Miners, AA Mangoni, A Rowland, AM Hopkins, ... JAMA oncology 6 (4), 512-518, 2020 | 189 | 2020 |
| Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers AM Hopkins, A Rowland, G Kichenadasse, MD Wiese, H Gurney, ... British journal of cancer 117 (7), 913-920, 2017 | 154 | 2017 |
| Interactive pharmacometric applications using R and the shiny package J Wojciechowski, AM Hopkins, RN Upton CPT: pharmacometrics & systems pharmacology 4 (3), 146-159, 2015 | 83 | 2015 |
| Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for NSCLC: pooled analysis of clinical trials MJ Sorich, A Rowland, CS Karapetis, AM Hopkins Journal of Thoracic Oncology 14 (8), 1440-1446, 2019 | 72 | 2019 |
| Concomitant antibiotic use and survival in urothelial carcinoma treated with atezolizumab AM Hopkins, G Kichenadasse, CS Karapetis, A Rowland, MJ Sorich European Urology 78 (4), 540-543, 2020 | 62 | 2020 |
| Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with AtezolizumabProton Pump Inhibitors and Immunotherapies AM Hopkins, G Kichenadasse, CS Karapetis, A Rowland, MJ Sorich Clinical Cancer Research 26 (20), 5487-5493, 2020 | 61 | 2020 |
| Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC–MS/MS H Rakhila, T Rozek, A Hopkins, S Proudman, L Cleland, M James, ... Journal of pharmaceutical and biomedical analysis 55 (2), 325-331, 2011 | 46 | 2011 |
| Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability AM Hopkins, A Rowland, MJ Sorich BMC medicine 16 (1), 165, 2018 | 31 | 2018 |
| Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150 AM Hopkins, G Kichenadasse, RA McKinnon, AY Abuhelwa, JM Logan, ... British journal of cancer 126 (1), 42-47, 2022 | 29 | 2022 |
| Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors AM Hopkins, G Kichenadasse, RA McKinnon, A Rowland, MJ Sorich Seminars in Oncology 46 (4-5), 380-384, 2019 | 29 | 2019 |
| Multiorgan immune-related adverse events during treatment with atezolizumab G Kichenadasse, JO Miners, AA Mangoni, A Rowland, AM Hopkins, ... Journal of the National Comprehensive Cancer Network 18 (9), 1191-1199, 2020 | 26 | 2020 |
| Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor AtezolizumabPrognostic Tool for … AM Hopkins, G Kichenadasse, E Garrett-Mayer, CS Karapetis, A Rowland, ... Clinical Cancer Research 26 (13), 3280-3286, 2020 | 26 | 2020 |
| Physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in drug exposure A Rowland, M Van Dyk, AM Hopkins, R Mounzer, TM Polasek, ... Clinical Pharmacology & Therapeutics 104 (6), 1219-1228, 2018 | 26 | 2018 |
| Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis AM Hopkins, MD Wiese, SM Proudman, CE O'Doherty, RN Upton, ... British journal of clinical pharmacology 81 (1), 113-123, 2016 | 25 | 2016 |
| Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs AY Abuhelwa, AM Hopkins, MJ Sorich, S Proudman, DJR Foster, ... Scientific reports 10 (1), 18634, 2020 | 20 | 2020 |
| Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift AM Hopkins, JM Logan, G Kichenadasse, MJ Sorich JNCI Cancer Spectrum 7 (2), pkad010, 2023 | 19 | 2023 |
| Selective isolation of liver-derived extracellular vesicles redefines performance of miRNA biomarkers for non-alcoholic fatty liver disease LA Newman, Z Useckaite, J Johnson, MJ Sorich, AM Hopkins, A Rowland Biomedicines 10 (1), 195, 2022 | 18 | 2022 |
| The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data ND Modi, JQE Tan, A Rowland, B Koczwara, AY Abuhelwa, ... NPJ Breast Cancer 7 (1), 30, 2021 | 17 | 2021 |
| Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy AEC Booth, AM Hopkins, A Rowland, G Kichenadasse, JR Smith, ... Therapeutic Advances in Medical Oncology 12, 1758835920944359, 2020 | 17 | 2020 |
| Semiphysiologically based pharmacokinetic model of leflunomide disposition in rheumatoid arthritis patients AM Hopkins, MD Wiese, SM Proudman, CE O'Doherty, DJR Foster, ... CPT: pharmacometrics & systems pharmacology 4 (6), 362-371, 2015 | 17 | 2015 |
Michael SorichProfessor of Clinical Pharmacology, Flinders University在 flinders.edu.au 的电子邮件经过验证
